Notable
Subcutaneous or Intravenous Doses of ADX-001 in Healthy Adults to Assess Safety, Effects, and Immune Response
Recruitment opened
Also in this update: Start date changed from estimate of Oct 6, 2026 to Oct 20, 2026
Adaxion TherapeuticsPhase 1 NCT07876076 Registry history of NCT07876076 on ClinicalTrials.gov (opens the registry)